Table 3.
Patient-Reported Outcomes After PRP Treatment for Hip Osteoarthritisa
| Follow-up | ||||
|---|---|---|---|---|
| Outcome Score | Pretreatment | Short-term (≤2 mo) | Midterm (4-6 mo) | Long-term (12 mo) |
| Battaglia (2013) 3 | ||||
| VAS | ||||
| PRP | 5.47 | 3.72 | 4.29 | 4.75 |
| HA | 5.97 | 3.58 | 4.04 | 4.59 |
| HHS | ||||
| PRP | 58.11 | 73.72 | 70.23 | 65.73 |
| HA | 62.90 | 78.02 | 75.79 | 72.55 |
| Dallari (2016) 13 | ||||
| VAS | ||||
| PRP | — | 2.3 | 2.1 | 2.4 |
| HA | — | 3.8 | 4.4 | 4.2 |
| PRP + HA | — | 3.5 | 3.5 | 3.8 |
| WOMAC | ||||
| PRP | — | 73 | 72 | — |
| HA | — | 59 | 59 | — |
| PRP + HA | — | 59 | 59 | — |
| HHS | ||||
| PRP | — | — | — | — |
| HA | — | — | — | — |
| PRP + HA | — | — | — | — |
| Di Sante (2016) 14 | ||||
| VAS | NR | |||
| PRP | 7.08 | 4.73 | 6.36 | |
| HA | 6.32 | 5.27 | 3.63 | |
| WOMAC–pain | NR | |||
| PRP | 58.8 | 44.2 | 53.4 | |
| HA | 42.3 | 29.6 | 19.9 | |
| WOMAC–stiffness | NR | |||
| PRP | 53.7 | 46.4 | 47.2 | |
| HA | 57.6 | 47.6 | 32.9 | |
| WOMAC–physical function | NR | |||
| PRP | 59.8 | 49.1 | 50.8 | |
| HA | 45.8 | 39.1 | 28.3 | |
| Doria (2017) 15 | ||||
| VAS | ||||
| PRP | 7.5 | NR | 6.3 | 6.4 |
| HA | 7.8 | NR | 6.3 | 6.1 |
| WOMAC–pain | ||||
| PRP | 23.7 | NR | 7.8 | 7.4 |
| HA | 24 | NR | 9.7 | 9 |
| WOMAC–stiffness | ||||
| PRP | 3.8 | NR | 2.1 | 2 |
| HA | 4.3 | NR | 3.1 | 3.1 |
| WOMAC–physical function | ||||
| PRP | 29.4 | NR | 12.3 | 12 |
| HA | 28.5 | NR | 11.3 | 10.9 |
| HHS | ||||
| PRP | 64 | NR | 75 | 78 |
| HA | 62 | NR | 74 | 75 |
aHA, hyaluronic acid; HHS, Harris Hip Score; NR, not reported; PRP, platelet-rich plasma; VAS, visual analog scale (scaled to 0-10); WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; —, data were reported as box plot graphs only.